Clinical Trials Logo

Cushing's Syndrome clinical trials

View clinical trials related to Cushing's Syndrome.

Filter by:

NCT ID: NCT05633953 Active, not recruiting - Cushing's Syndrome Clinical Trials

Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

LINC7
Start date: January 16, 2023
Phase:
Study type: Observational

This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients. Patients treated with oral osilodrostat regardless of the duration of their treatment will be followed retrospectively for up to 36 months after initiating osilodrostat.

NCT ID: NCT03817840 Completed - Cushing's Syndrome Clinical Trials

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

Start date: July 16, 2018
Phase:
Study type: Observational

This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them. The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushing's syndrome, either from taking steroid medications or from tumors, impact body fat and metabolism by turning off brown fat, which is a type of fat that increases one's metabolism.

NCT ID: NCT03606408 Active, not recruiting - Cushing's Syndrome Clinical Trials

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Start date: October 5, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.

NCT ID: NCT02922257 Completed - Cushing's Syndrome Clinical Trials

Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

Start date: November 2016
Phase:
Study type: Observational

This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3 beta [GSK3b]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical treatment, and detection of relapse of endogenous Cushing's syndrome after surgery.

NCT ID: NCT02889224 Completed - Cushing's Syndrome Clinical Trials

In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man

VISECA
Start date: February 2012
Phase: N/A
Study type: Interventional

Working hypothesis: the interactions between the endogenous endocannabinoïds (ECS) - and cortisol, the end product of the Hypothalamo-Pituitary-Adrenal (HPA) axis may play a role in the pathophysiology of Cushing's syndrome. The investigators speculate that: - acute or chronic variations in plasma cortisol may induce changes in the activity of the ECS - that there is a circadian rhythm of the ECS driven by the rythm of plasma cortisol

NCT ID: NCT02804750 Completed - Cushing's Syndrome Clinical Trials

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Start date: June 2016
Phase: Phase 2
Study type: Interventional

Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol. Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, were not eligible for enrollment in this study. The purpose of this study was to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study was conducted in the United States and in Europe.

NCT ID: NCT02663609 Completed - Cushing's Syndrome Clinical Trials

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

RE-KLAIM
Start date: October 2015
Phase:
Study type: Observational

Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.

NCT ID: NCT02468193 Completed - Cushing's Syndrome Clinical Trials

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Start date: September 24, 2015
Phase: Phase 2
Study type: Interventional

The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.

NCT ID: NCT02297945 Completed - Cushing's Syndrome Clinical Trials

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

PROMPT
Start date: April 2015
Phase: Phase 3
Study type: Interventional

The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.

NCT ID: NCT02019706 Recruiting - Cushing's Syndrome Clinical Trials

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

Start date: February 12, 2014
Phase: Phase 2
Study type: Interventional

Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral source of ACTH cannot be found initially despite very detailed and extensive imaging, including studies such as computed tomography, magnetic resonance imaging, and octreotide scan (Octreoscan) using the standard dose of indium- 111 pentetreotide ([111In-DTPA-D-Phe]-pentetreotide). The sensitivity and specificity of structurally based imaging studies depends on anatomic alterations and the size of the tumor. In contrast, positron emission tomography (PET) and somatostatin ligand imaging detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This protocol tests the ability of [18F]-L-3,4-dihydroxyphenylalanine (18F-DOPA) PET, and the somatostatin imaging analogue, 68Ga-DOTATATE-PET, to localize the source of ectopic ACTH production.